Loading...
XNAS
MDXH
Market cap18mUSD
Jul 09, Last price  
0.49USD
1D
-1.03%
1Q
-75.99%
IPO
-95.92%
Name

MDxHealth SA

Chart & Performance

D1W1MN
XNAS:MDXH chart
P/E
—
P/S
0.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
43.16%
Rev. gr., 5y
42.34%
Revenues
108m
+19.80%
3,657,1683,850,5834,209,7053,650,6393,372,7883,482,5994,918,4017,554,00011,479,00017,467,00029,867,00040,508,00028,338,00011,785,00018,460,00022,239,00037,054,00070,193,00090,049,000107,875,000
Net income
-34m
L-11.95%
0000000-16,175,000-15,256,000-14,473,000-13,174,000-12,288,000-32,450,000-43,100,000-28,662,000-29,002,000-44,044,000-43,100,000-38,069,000-33,519,000
CFO
-10m
L-43.78%
0000000-14,105,000-18,513,000-14,394,000-16,585,000-10,489,000-28,543,000-22,289,000-20,244,000-22,548,000-34,118,000-21,497,000-18,530,000-10,417,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
URL
https://mdxhealth.com/
IPO date
Jun 26, 2006
Employees
252
Domiciled in
BE
Incorporated in
BE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT